Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)

被引：3
作者：
Sznol, M. [1 ]
Ferrucci, P. F. [2 ]
Hogg, D. [3 ]
Atkins, M. [4 ]
Wolter, P. [5 ]
Guidoboni, M. [6 ]
Lebbe, C. [7 ]
Kirkwood, J. [8 ]
Schachter, J. [9 ]
Daniels, G. [10 ]
Hassel, J. [11 ]
Cebon, J. [12 ]
Gerritsen, W. [13 ]
Atkinson, V. [14 ,15 ]
Thomas, L. [16 ]
McCaffrey, J. [17 ]
Power, D. [18 ]
Jiang, J. [19 ]
Hodi, F. S. [20 ]
Wolchok, J. [21 ]
机构：
[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA
[2] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy
[3] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada
[4] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA
[5] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[6] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy
[7] Hop St Louis, Dermatol, Paris, France
[8] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA
[9] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel
[10] Moores UCSD Canc Ctr, Med, La Jolla, CA USA
[11] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany
[12] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia
[13] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands
[14] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia
[15] Princess Alexandra Hosp, Greenslopes, Australia
[16] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France
[17] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland
[18] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland
[19] BMS, Oncol, Princeton, NJ USA
[20] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA
[21] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw379.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1123P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overall Survivalwith Nivolumab (NIVO) and Ipilimumab (IPI) Combination Therapy in a Phase III Trial of Advanced Melanoma (CHECKMATE 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J-J
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Walker, D.
    Rollin, L.
    Horak, C.
    Hodi, F. S.
    Wolchok, J. D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 48 - 48
  • [22] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040
    He, Aiwu Ruth
    Yau, Thomas
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Tschaika, Marina
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
    Postow, Michael
    Chesney, Jason
    Pavlick, Anna
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv
    Shaheen, Montaser
    Ernstoff, Marc
    Minor, David
    Salama, April
    Taylor, Matthew
    Ott, Patrick
    Jiang, Joel
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd
    Hodi, F. Stephen
    CANCER RESEARCH, 2016, 76
  • [24] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO
    Schadendorf, D.
    Ugurel, S.
    Eigentler, T.
    Mohr, P.
    Wei-Chenthal, M.
    Gebhardt, C.
    Goppner, D.
    Haferkamp, S.
    Herbst, R.
    Kahler, K.
    Kreuter, A.
    Meier, F.
    Pfohler, C.
    Sachse, M. M.
    Sickmann, T.
    Terheyden, P.
    Ulrich, J.
    Utikal, J. S.
    Grimmel-Mann, I.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17
  • [25] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    El-Khoueiry, Anthony B.
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Baccan, Carlos
    Dela Cruz, Christine Marie
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, C. Lance
    Lao, Christopher
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Walker, Dana
    Jiang, Joel
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Hodi, F. Stephen
    Lao, Christopher D.
    Moschos, Stergios J.
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl D.
    Thomas, Reena Parada
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain Patrick
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc S.
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine I.
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Wagstaff, John
    Hogg, David
    Hill, Andrew
    Carlino, Matteo S.
    Wolter, Pascal
    Lebbe, Celeste
    Schachter, Jacob
    Thomas, Luc
    Hassal, Jessica C.
    Lorigan, Paul
    Walker, Dana
    Jiang, Joel
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 126 - 126
  • [30] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Hogg, D.
    Hill, A.
    Carlino, M. S.
    Wolter, P.
    Lebbe, C.
    Schachter, J.
    Thomas, L.
    Hassel, J. C.
    Lorigan, P.
    Walker, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S664 - S665
12345